Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1987 2
1988 2
1990 2
1991 1
1993 5
1994 4
1995 1
1996 1
1997 3
1998 1
1999 1
2001 1
2002 12
2003 7
2004 7
2005 7
2006 7
2007 9
2008 10
2009 13
2010 12
2011 21
2012 18
2013 17
2014 17
2015 31
2016 27
2017 28
2018 33
2019 27
2020 30
2021 22
2022 23
2023 27
2024 9

Text availability

Article attribute

Article type

Publication date

PubMed for id: 124512

386 results

Results by year

Filters applied: . Clear all
Page 1
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.
Woyach JA, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, Eathiraj S, Reiff SD, Muhowski EM, Granlund L, Szuszkiewicz L, Wang W, Schwartz B, Ghori R, Farooqui MZH, Byrd JC. Woyach JA, et al. Cancer Discov. 2024 Jan 12;14(1):66-75. doi: 10.1158/2159-8290.CD-23-0670. Cancer Discov. 2024. PMID: 37930156 Clinical Trial.
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.
Hill BT, Ma S, Zent CS, Baran AM, Wallace DS, Advani A, Winter A, Winter J, Gordan L, Karmali R, Liesveld JL, Mulford DA, Rowland C, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Barr PM. Hill BT, et al. Blood Adv. 2024 Jan 23;8(2):378-387. doi: 10.1182/bloodadvances.2023010693. Blood Adv. 2024. PMID: 37871300 Free PMC article.
Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial.
Tam CS, Lamanna N, O'Brien SM, Qiu L, Yang K, Barnes G, Wu K, Salmi T, Brown JR. Tam CS, et al. Curr Med Res Opin. 2023 Sep 27:1-7. doi: 10.1080/03007995.2023.2262378. Online ahead of print. Curr Med Res Opin. 2023. PMID: 37752892
386 results